Abstract
Immunotherapy based on adoptive transfer of tumor antigen-specific CD8(+) T cell (TC) is generally limited by poor in vivo expansion and tumor infiltration. In this study, we report that activated STAT5 transcription factors (STAT5CA) confer high efficiency on CD8(+) effector T cells (eTC) for host colonization after adoptive transfer. Engineered expression of STAT5CA in antigen-experienced TCs with poor replicative potential was also sufficient to convert them into long-lived antigen-responsive eTCs. In transplanted mastocytoma- or melanoma-bearing hosts, STAT5CA greatly enhanced the ability of eTCs to accumulate in tumors, become activated by tumor antigens, and to express the cytolytic factor granzyme B. Taken together, these properties contributed to an increase in tumor regression by STAT5CA-transduced, as compared with untransduced, TCs including when the latter control cells were combined with infusion of interleukin (IL)-2/anti-IL-2 complexes. In tumors arising in the autochthonous TiRP transgenic model of melanoma associated with systemic chronic inflammation, endogenous CD8(+) TCs were nonfunctional. In this setting, adoptive transfer of STAT5CA-transduced TCs produced superior antitumor effects compared with nontransduced TCs. Our findings imply that STAT5CA expression can render TCs resistant to the immunosuppressive environment of melanoma tumors, enhancing their ability to home to tumors and to maintain high granzyme B expression, as well as their capacity to stimulate granzyme B expression in endogenous TCs.
Highlights
The discovery of tumor antigens recognized by autologousT cells (TC) in patients with melanoma has led to clinical protocols for adoptive transfer of tumor antigen-specific TCs.The efficacy of this treatment remains poor [1,2,3], for several reasons
STAT5 transcription factors (STAT5CA)-expressing CD8þ effector TCs (eTC) are more efficient than control CD8þ eTCs for host colonization upon adoptive transfer and show increased accumulation in nonlymphoid tissues
CD8þ TCs expressing a transgenic-TCR (TCRP1A) specific for peptide P1A35–43 encoded by mouse P1A cancer germline gene were activated in vitro
Summary
The discovery of tumor antigens recognized by autologous. T cells (TC) in patients with melanoma has led to clinical protocols for adoptive transfer of tumor antigen-specific TCs. T cells (TC) in patients with melanoma has led to clinical protocols for adoptive transfer of tumor antigen-specific TCs The efficacy of this treatment remains poor [1,2,3], for several reasons. Naive CD8þ TCs must differentiate into effector TCs (eTC) acquiring lytic enzyme-containing granules and the capacity to secrete cytokines. Tumor antigen-specific TCs may undergo incomplete differentiation [4] or be tolerized upon encounter with tumor antigen [5]. During prolonged antigen contact within tumors, CD8þ TCs may become functionally impaired and subsequently deleted
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.